CXC-Type Chemokines Promote Myofibroblast Phenoconversion and Prostatic Fibrosis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Gharaee Kermani, Mehrnaz ^a   Kasina, Sathish ^a   Moore, Bethany B ^a   Thomas, Dafydd ^a   Mehra, Rohit ^a   Macoska, Jill A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ALPHA SMOOTH MUSCLE ACTIN; CALPONIN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; COLLAGEN TYPE 3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 8; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LOWER URINARY TRACT SYMPTOM; MALE; MYOFIBROBLAST; PATHOGENESIS; PHENOTYPE; PROSTATIC FIBROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DIFFERENTIATION;

CELL DIFFERENTIATION; CELLULAR MICROENVIRONMENT; CHEMOKINES, CXC; FIBROSIS; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MYOFIBROBLASTS; PROSTATE; TRANSCRIPTION, GENETIC;

EID: 84869228802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049278     Document Type: Article

References (74)

1. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB, (2001) Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54: 935-944.
2. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, et al. (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 42: 323-328.
3. McVary KT, (2007) A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 29: 387-398.
4. Wei JT, Calhoun E, Jacobsen SJ, (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173: 1256-1261.
5. Laborde EE, McVary KT, (2009) Medical management of lower urinary tract symptoms. Rev Urol 11: S19-25.
6. Gur S, Kadowitz PJ, Hellstrom WJ, (2008) Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: implications for sexual dysfunction. Drugs 68: 209-229.
7. Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, et al. (2012) Prostatic Fibrosis is Associated with Lower Urinary Tract Symptoms. J Urol 188: 1375-1381.
8. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, et al. (2009) TGF-β and fibrosis in different organs - molecular pathway imprints. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease 1792: 746-756.
9. Hinz B, (2007) Formation and Function of the Myofibroblast during Tissue Repair. Journal of Investigative Dermatology 127: 526-537.
10. Wynn TA, (2008) Cellular and molecular mechanisms of fibrosis. The Journal of Pathology 214: 199-210.
11. Detlefsen S, Sipos B, Feyerabend B, Klöppel G, (2005) Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Archiv 447: 800-805.
12. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, et al. (2008) Islet Inflammation in Type 2 Diabetes: From metabolic stress to therapy. Diabetes Care 31: S161-S164.
13. Scotton CJ, Chambers RC, (2007) Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus. Chest 132: 1311-1321.
14. Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR, (2009) Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Curr Med Chem 16: 1400-1417.
15. Frith J, Day CP, Henderson E, Burt AD, Newton JL, (2009) Non-Alcoholic Fatty Liver Disease in Older People. Gerontology 55: 607-613.
16. Novo E, Valfrè di Bonzo L, Cannito S, Colombatto S, Parola M, (2009) Hepatic myofibroblasts: A heterogeneous population of multifunctional cells in liver fibrogenesis. The International Journal of Biochemistry & Cell Biology 41: 2089-2093.
17. Rieder F, Fiocchi C, (2009) Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nature Reviews Gastroenterology & Hepatology 6: 228-235.
18. Goldacre MJ, (2009) Demography of aging and the epidemiology of gastrointestinal disorders in the elderly. Best Practice & Research Clinical Gastroenterology 23: 793-804.
19. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, et al. (1992) Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66: 96-107.
20. Nickel JC, Downey J, Young I, Boag S, (1999) Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84: 976-981.
21. Okada H, Danoff TM, Fischer A, Lopez-Guisa JM, Strutz F, et al. (1998) Identification of a novel cis-acting element for fibroblast-specific transcription of the FSP1 gene. Am J Physiol 275: F306-314.
22. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923.
23. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR, (2008) Elevated Epithelial Expression of Interleukin-8 Correlates with Myofibroblast Reactive Stroma in Benign Prostatic Hyperplasia. Urology 72: 205-213.
24. Schauer IG, Ressler SJ, Rowley DR, (2009) Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. The Prostate 69: 373-384.
25. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA, (2010) Leukocytic promotion of prostate cellular proliferation. Prostate 70: 377-389.
26. Begley LA, MacDonald JW, Day ML, Macoska JA, (2007) CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 282: 26767-26774.
27. Begley LA, Kasina S, MacDonald J, Macoska JA, (2008) The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 43: 194-199.
28. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA, (2005) CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4: 291-298.
29. Macoska JA, Paris P, Collins C, Andaya A, Beheshti B, et al. (2004) Evolution of 8p loss in transformed human prostate epithelial cells. Cancer Genet Cytogenet 154: 36-43.
30. Kasina S, Macoska JA, (2012) The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol 351: 249-263.
31. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
32. Cunnington RH, Wang B, Ghavami S, Bathe KL, Rattan SG, et al. (2011) Antifibrotic properties of c-Ski and its regulation of cardiac myofibroblast phenotype and contractility. Am J Physiol Cell Physiol 300: C176-186.
33. Begley L, Keeney D, Beheshti B, Squire JA, Kant R, et al. (2006) Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes Cancer 45: 136-146.
34. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat M-L, et al. (2007) The Myofibroblast. The American Journal of Pathology 170: 1807-1816.
35. Tuxhorn JA (2002) Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling.
36. Hinz B, (2010) The myofibroblast: paradigm for a mechanically active cell. J Biomech 43: 146-155.
37. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, et al. (1998) AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4: 72-77.
38. Jinnin M, (2010) Mechanisms of skin fibrosis in systemic sclerosis. The Journal of Dermatology 37: 11-25.
39. Huang X, Lee C, (2003) Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta. Front Biosci 8: s740-749.
40. San Francisco IF, DeWolf WC, Peehl DM, Olumi AF, (2004) Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. International Journal of Cancer 112: 213-218.
41. Kramer G, Mitteregger D, Marberger M, (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51: 1202-1216.
42. Zhao H, Patra A, Yeh CC, Tanaka Y, Oh BR, et al. (2002) Effects of aging on growth factors gene and protein expression in the dorsal and ventral lobes of rat prostate. Biochem Biophys Res Commun 292: 482-491.
43. Mori H, Maki M, Oishi K, Jaye M, Igarashi K, et al. (1990) Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 16: 71-80.
44. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, et al. (1995) Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628-635.
45. Royuela M, De Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, et al. (1998) Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors 16: 101-110.
46. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92: 9363-9367.
47. Nishimura F, Terranova VP, Braithwaite M, Orman R, Ohyama H, et al. (1997) Comparison of in vitro proliferative capacity of human periodontal ligament cells in juvenile and aged donors. Oral Dis 3: 162-166.
48. Kajstura J, Pertoldi B, Leri A, Beltrami CA, Deptala A, et al. (2000) Telomere shortening is an in vivo marker of myocyte replication and aging. Am J Pathol 156: 813-819.
49. Hjelmeland LM, (1999) Senescence of the retinal pigmented epithelium. Invest Ophthalmol Vis Sci 40: 1-2.
50. Chkhotua A, Shohat M, Tobar A, Magal N, Kaganovski E, et al. (2002) Replicative senescence in organ transplantation-mechanisms and significance. Transpl Immunol 9: 165-171.
51. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
52. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, et al. (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66: 794-802.
53. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, et al. (2009) Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation. The Journal of Immunology 182: 4056-4064.
54. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, et al. (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273: 10095-10098.
55. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, et al. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382: 829-833.
56. International Union of Immunological Societies/World Health Organization Subcommittee on chemokine nomenclature (2001) Chemokine/chemokine receptor nomenclature. J Leukoc Biol 70: 465-466.
57. Xie Y, Chen J, Han P, Yang P, Hou J, et al. (2012) Immunohistochemical detection of differentially localized up-regulation of lysyl oxidase and down-regulation of matrix metalloproteinase-1 in rhesus monkey model of chronic myocardial infarction. Exp Biol Med (Maywood) 237: 853-859.
58. Van Hoozen BE, Grimmer KL, Marelich GP, Armstrong LC, Last JA, (2000) Early phase collagen synthesis in lungs of rats exposed to bleomycin. Toxicology 147: 1-13.
59. Wang J, Wang Q, Watson LJ, Jones SP, Epstein PN, (2011) Cardiac overexpression of 8-oxoguanine DNA glycosylase 1 protects mitochondrial DNA and reduces cardiac fibrosis following transaortic constriction. Am J Physiol Heart Circ Physiol 301: H2073-2080.
60. Syed F, Ahmadi E, Iqbal SA, Singh S, McGrouther DA, et al. (2011) Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol 164: 83-96.
61. Rodrigues AA Jr, Suaid HJ, Fazan VP, Reis RB, Cologna AJ, et al. (2011) Histologic study of urethral extracellular matrix and collagen from aging and long-term alloxan-induced diabetic male rats. Urology 77: 510 e516-511.
62. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, et al. (1990) Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492-1497.
63. Deering RE, Bigler SA, King J, Choongkittaworn M, Aramburu E, et al. (1994) Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology 44: 64-70.
64. Arenas MI, Romo E, Royuela M, Ruiz A, Fraile B, et al. (2001) Morphometric evaluation of the human prostate. Int J Androl 24: 37-47.
65. Schotten U, Verheule S, Kirchhof P, Goette A, (2011) Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91: 265-325.
66. Morales MG, Cabello-Verrugio C, Santander C, Cabrera D, Goldschmeding R, et al. (2011) CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. The Journal of Pathology 225: 490-501.
67. Somoza B, Abderrahim F, Gonzalez J, Conde M, Arribas S, et al. (2006) Short-term treatment of spontaneously hypertensive rats with liver growth factor reduces carotid artery fibrosis, improves vascular function, and lowers blood pressure. Cardiovascular Research 69: 764-771.
68. Elbadawi A, Yalla SV, Resnick NM, (1993) Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 150: 1657-1667.
69. Gosling JA, (1997) Modification of bladder structure in response to outflow obstruction and ageing. Eur Urol 32Suppl 1: 9-14.
70. Charlton RG, Morley AR, Chambers P, Gillespie JI, (1999) Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int 84: 953-960.
71. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, et al. (2006) Histologic Features in the Urinary Bladder Wall Affected from Neurogenic Overactivity-A Comparison of Inflammation, Oedema and Fibrosis With and Without Injection of Botulinum Toxin Type A. European Urology. 50: 1058-1064.
72. Lepor H, Sunaryadi I, Hartanto V, Shapiro E, (1992) Quantitative morphometry of the adult human bladder. J Urol 148: 414-417.
73. Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, et al. (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 166: 2381-2387.
74. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E, (2008) Prevalence and characteristics of lower urinary tract symptoms in men aged >or = 80 years. Urology 72: 318-321.